MAM
Colgate Active Salt redefines oral hygiene with a new and improved formula
Mumbai: Colgate-Palmolive (India) Ltd has announced the launch of the renewed Colgate Active Salt, setting a new benchmark in oral hygiene solutions with an improved formula that tackles oral problems right at their inception.
Since 2005, Colgate Active Salt has served the nation by addressing early oral concerns, leveraging the unique benefits of salt ingrained in Indian oral care traditions. It is also Colgate’s number one brand in Tamil Nadu. Building upon this legacy, the all-new Colgate Active Salt introduces an improved and more potent formula to nip oral problems in the bud.
Speaking on the launch, Colgate-Palmolive India Sr marketing manager Ayan Guha said, “By unveiling the upgraded Colgate Active Salt, we celebrate the timeless wisdom ingrained in the power of salt, enhanced by Colgate’s science-led approach. Supported by a new campaign, we continue the journey of dramatic Colgate Active Salt advertising that has made the brand iconic over two decades.”
WPP@CP executive creative director Juneston Mathana added, “Whoever says they don’t fear the consequences of dental pain is clearly lying. We’ve all felt it, we’ve all feared it. It’s a pain that sends shivers down the spines of the most powerful people out there. This idea got our director, Harshik Suraiya, excited because it exposes our vulnerabilities in a relatable and light-hearted way.”
The ad film aims to underscore the importance of proactive oral care in an engaging manner, featuring a victorious politician, riding high on his recent win, is abruptly interrupted by a toothache after indulging in celebratory sweets. The events that unfold thereafter serve as a vivid reminder that oral discomfort can strike unexpectedly but with Colgate Active Salt, you can say goodbye to pain and fear!
The campaign has been rolled out in Southern and Eastern markets , across television, digital and other media platforms. Colgate Active Salt is available nationwide through both online and offline channels.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
